Skip to main content
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
As of Apr 2
Health1 sourcesNeutral

Caliway Selected To Present Preclinical Data On CBL-514 In Combination With GLP-1R Therapy At The American Diabetes Association's 2026 Scientific Sessions

(MENAFN - PR Newswire) Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the ...

Menafn
via Menafn
Caliway Selected To Present Preclinical Data On CBL-514 In Combination With GLP-1R Therapy At The American Diabetes Association's 2026 Scientific Sessions

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Comments

0 comments
Be respectful and constructive.
Loading comments...